期刊
CLINICAL COLORECTAL CANCER
卷 21, 期 3, 页码 198-203出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clcc.2022.05.006
关键词
Immunotherapy; Clinical trials; Targeted therapy; Colon cancer; Circulating tumor DNA
类别
Colon cancer requires better screening and treatment options, especially with the rising incidence in the young population. Circulating tumor DNA and immunotherapy offer potential advancements in treatment, but face challenges in broader efficacy. Targeted therapies are a viable option for patients with poor prognosis.
Colon cancer needs better screening and treatment options. Its incidence in the young population is rising. Recent changes in guidelines recommend beginning screening for colon cancer at the age of 45. Circulating tumor DNA presents an opportunity to select patients for administration of adjuvant chemotherapy. Immunotherapy is an option for patients with a deficiency in mismatch repair proteins. However, its efficacy outside of this group of patients remains a challenge. Targeted therapies such as BRAF inhibitors are an option for patients with poor prognosis, for whom cytotoxic chemotherapy is not as effective. This review presents the recently published evidence regarding screening and treating patients with colon cancer. (C) 2022 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据